MaxCyte Investor Presentation Deck

VLX-Enabled Approach for Biotherapeutic Development Traditional M MaxCyte Target Validation and Lead Selection Discovery Transient Expression Seed Train Expansion Pre-Clinical (lead) X X Cell Concentration & Buffer Exchange (CCBE) X Pre-Clinical Transient Expression VLX-Enabled Approach*: ~1-2 months IND Filing Stable Cell Line Stable Cell Line Development: ~6+ months Cell Recovery VLX Electroporation M MaxCyte cGMP Optimized Workflow 19 = Cell Culture & Bioproduction Phase I Phase II M MaxCyte Clinical cGMP Stable Cell Line Phase III *MaxCyte's VLx workflow enables production of multi-gram quantity of transiently-produced proteins in-house in only 4-6 weeks for use in pre-clinical and early-clinical studies.

View entire presentation